Trial
NCT06111014
Continuation Study for Latozinemab
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Alector Inc.
Collaborators
—
Condition
Neurodegenerative Diseases
Intervention
Latozinemab
Why stopped
The AL001-CS-302 study was terminated because its Phase 3 placebo-controlled parent study (AL001-3) failed to meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-21